IL6 and neoplasm: These studies were carried out in the context of the primary tumor and not metastatic disease, but these data are consistent with the observed tumor-promoting effects of IL-6 on bone-disseminated tumor cells and it is therefore possible that some of these effects may be mediated through IL-30-driven IL-6 signaling.